Last updated: September 17, 2026
Drospirenone and estetrol are commercialized together in Nextstellis, an oral combined hormonal contraceptive developed by Mithra Pharmaceuticals and commercialized in the United States by Mayne Pharma. The product received FDA approval in April 2021 and entered a contraceptive market dominated by low-cost generics, established branded pills, long-acting reversible contraceptives, and over-the-counter alternatives.
Nextstellis has a differentiated clinical profile because estetrol is a naturally occurring estrogen with selective tissue activity, while drospirenone is an established progestin with antimineralocorticoid and antiandrogenic properties. Its commercial opportunity depends on premium pricing, prescriber adoption, insurance coverage, patient access, and the ability to maintain differentiation after FDA regulatory exclusivity ends.
The principal commercial risk is market structure. Nextstellis competes against generic ethinyl estradiol/drospirenone products, including generic Yaz equivalents, which have materially lower acquisition costs. The principal legal risk is future generic entry after the product’s NCE exclusivity period and the resolution of patent challenges.
What is the commercial product containing drospirenone and estetrol?
Nextstellis contains 14.2 mg of estetrol monohydrate and 3 mg of drospirenone per active tablet. The 28-day regimen includes 24 active tablets followed by four inactive tablets. It is indicated for the prevention of pregnancy in females of reproductive potential.
| Attribute |
Nextstellis |
| Active ingredients |
Estetrol monohydrate and drospirenone |
| Dosage form |
Oral tablet |
| Therapeutic class |
Combined hormonal contraceptive |
| U.S. approval |
April 15, 2021 |
| U.S. commercial partner |
Mayne Pharma |
| Originator |
Mithra Pharmaceuticals |
| FDA pathway |
New drug application |
| U.S. exclusivity type |
New chemical entity exclusivity for estetrol |
| Primary competitors |
Yaz, Nikki, Gianvi, Loryna, generic drospirenone/ethinyl estradiol |
| Biosimilar exposure |
None; this is a small-molecule drug |
The product was originally commercialized in the United States under an agreement between Mithra and Mayne Pharma. Mayne obtained exclusive U.S. commercial rights and assumed responsibility for commercialization, market access, and distribution in the U.S. market (Mayne Pharma, 2021).
How does drospirenone and estetrol compare with generic drospirenone and ethinyl estradiol?
Nextstellis competes most directly with generic drospirenone/ethinyl estradiol products rather than with single-ingredient drospirenone products. Its clinical positioning is based on the use of estetrol instead of ethinyl estradiol.
| Market factor |
Nextstellis |
Generic drospirenone/ethinyl estradiol |
| Estrogen component |
Estetrol |
Ethinyl estradiol |
| Progestin |
Drospirenone |
Drospirenone |
| Brand status |
Branded |
Generic |
| Price position |
Premium |
Low-cost |
| Clinical differentiation |
Novel estrogen and differentiated pharmacology |
Established reference formulation |
| Prescriber familiarity |
Developing |
High |
| Pharmacy substitution |
Limited |
Strong |
| Payer leverage |
Challenging |
Favorable |
| Generic competition |
Future risk |
Existing |
Generic drospirenone/ethinyl estradiol products benefit from extensive prescriber familiarity and broad formulary access. Many payers require generic substitution or impose prior authorization on Nextstellis. This creates a commercial barrier even when clinicians view the product as clinically differentiated.
Nextstellis can obtain premium positioning where patients or prescribers value its estrogen profile, tolerability, bleeding characteristics, or perceived safety advantages. The commercial proposition is weaker in plans that treat oral contraceptives as interchangeable products.
What is the FDA regulatory status and exclusivity timeline for Nextstellis?
The FDA approved Nextstellis on April 15, 2021. The approval made estetrol a new active estrogenic moiety in the U.S. contraceptive market. The product’s principal FDA exclusivity protection was five-year new chemical entity exclusivity associated with estetrol.
| Milestone |
Date or period |
| FDA approval |
April 15, 2021 |
| Five-year NCE exclusivity |
Runs through approximately April 2026 |
| Earliest conventional ANDA timing |
Approximately April 2025 for a Paragraph IV filing |
| Likely first generic launch opportunity |
Dependent on patents, litigation, and settlement terms |
| Pediatric exclusivity |
No broadly reported pediatric extension associated with the product |
| Regulatory category |
Small-molecule NDA product |
NCE exclusivity blocks the FDA from approving an abbreviated new drug application referencing the protected new active moiety during the exclusivity period. It does not prevent a competitor from filing an ANDA during the fourth year with a Paragraph IV certification against listed patents.
The end of NCE exclusivity does not automatically create generic entry. Generic launch depends on the Orange Book patent listings, the timing of ANDA filings, Paragraph IV litigation, 30-month stays, settlements, and any court decision invalidating or not-infringing the asserted patents.
What patents protect drospirenone and estetrol?
The product’s protection is based on a combination of composition, formulation, pharmaceutical-use, and manufacturing rights rather than on the basic drospirenone molecule. Drospirenone has long-standing prior-art exposure and is not, by itself, a durable exclusivity platform for Nextstellis.
The more important intellectual-property assets relate to:
- Compositions containing estetrol and drospirenone.
- Oral dosage forms with defined ratios and release characteristics.
- Estetrol formulations designed to improve stability, dissolution, or bioavailability.
- Contraceptive methods using estetrol with drospirenone.
- Manufacturing and purification processes for estetrol.
- Crystalline forms, salts, solvates, or intermediates where separately patented.
Mithra’s broader estetrol patent estate covers the use of estetrol in hormonal therapies and contraceptive products. Some rights are product-specific, while others may cover wider estrogen formulations. The practical value of a patent depends on its claim scope, Orange Book listing status, patent-term adjustment, terminal disclaimers, prosecution history, and ability to survive an invalidity challenge.
What is the Orange Book status of Nextstellis?
Nextstellis is an FDA-approved NDA product and is eligible for Orange Book patent listings if the relevant patents claim the approved drug, its formulation, or an approved method of use. Orange Book-listed patents can support Paragraph IV litigation against an ANDA applicant.
The commercially relevant questions are:
- Which patents were listed against the approved product?
- Which patents expire first?
- Do the claims cover the drug product itself or only specific uses?
- Does a Paragraph IV challenge trigger a 30-month stay?
- Has the patent holder entered a settlement that controls the generic launch date?
Patent expiration should not be inferred solely from the original filing date. U.S. patent-term adjustment, terminal disclaimers, patent-term extension, and continuations can materially affect the effective protection period.
Publicly disclosed patent activity around estetrol and estetrol-containing formulations indicates protection extending beyond FDA NCE exclusivity and into the 2030s for some claims. The practical loss-of-exclusivity date is therefore likely to be determined by the strongest surviving composition or formulation patent, not by the April 2026 end of NCE exclusivity.
When does Nextstellis lose exclusivity?
Nextstellis faces two separate exclusivity cliffs.
The first is regulatory. Estetrol’s five-year NCE exclusivity ends in approximately April 2026. After that point, the FDA can approve an ANDA if the applicant satisfies all regulatory requirements and any patent barriers have been removed.
The second is patent-based. Patent protection may extend into the 2030s, depending on which claims are listed, challenged, upheld, or settled. A generic company can enter before the latest patent expiry if it prevails in litigation, reaches a settlement, or launches at risk.
| Protection layer |
Commercial effect |
| NCE exclusivity |
Delays ANDA approval based on estetrol until approximately April 2026 |
| Composition patents |
Can block or delay products containing the claimed combination |
| Formulation patents |
Can block specific tablet formulations or release profiles |
| Method-of-use patents |
May require a skinny-label strategy or support litigation |
| Manufacturing patents |
Can raise supply-chain and process-replication barriers |
| Patent settlements |
Can establish an agreed generic entry date |
| Patent invalidity ruling |
Can accelerate entry before nominal expiry |
Are there Paragraph IV challenges to Nextstellis?
A Paragraph IV challenge is the principal pathway for a generic applicant seeking approval before the expiry of listed patents. The applicant certifies that a listed patent is invalid, unenforceable, or will not be infringed by the proposed product.
The known commercial consequences are:
- The ANDA filer can trigger patent litigation after notice to the NDA holder.
- Filing of an infringement suit can create a 30-month FDA approval stay.
- The first qualifying Paragraph IV filer may receive 180-day generic exclusivity.
- A settlement can postpone entry while preserving value for both parties.
- A court ruling can determine whether combination, formulation, or use claims survive.
The generic challenge risk is lower for claims directed narrowly to a branded tablet or a particular formulation and higher for broad claims covering the estetrol/drospirenone combination. Composition claims generally present the largest barrier because a successful generic product may necessarily practice them.
No biosimilar pathway applies. Nextstellis is a small-molecule product, so competition will arise through ANDAs, not biosimilar applications.
How strong is the patent estate for drospirenone and estetrol?
The patent estate is stronger than the product’s regulatory exclusivity alone but weaker than the estate of a novel biologic or a platform drug with multiple independent indications.
Strengths
- Estetrol gives the product a novel active-moiety component in the U.S.
- Combination claims can cover the specific product architecture.
- Formulation patents may create additional barriers after NCE exclusivity.
- Estetrol manufacturing and purification can create know-how and process barriers.
- The originator can use method-of-use patents to complicate a full-label generic launch.
Weaknesses
- Drospirenone is an established generic progestin.
- Oral contraceptive formulations are exposed to extensive prior art.
- A generic may design around narrow formulation claims.
- Method-of-use patents may be less effective if a generic uses a skinny label.
- The product has a single principal contraceptive indication.
- Low-cost generic substitutes weaken the commercial value of delayed entry.
The estate is commercially meaningful but must be evaluated claim by claim. The key question is whether a generic can obtain approval without infringing a surviving composition or formulation patent, not whether the originator holds a large number of patents.
What is the financial trajectory for Nextstellis?
Nextstellis entered a large market but started from a difficult financial position. Mayne Pharma had to build a new brand against entrenched generics while paying for sales infrastructure, market access, patient support, and physician education.
The financial trajectory has four phases.
Launch phase: 2021 to 2022
The initial period required investment in:
- Physician promotion.
- Direct-to-consumer education.
- Specialty pharmacy and retail distribution.
- Insurance reimbursement.
- Patient savings and affordability programs.
- Awareness of estetrol as a new estrogen component.
Revenue growth was constrained by low brand recognition and the need to establish payer coverage. New contraceptive brands commonly experience a long conversion cycle because prescribers can choose among numerous generic products.
Scale-up phase: 2023 to 2025
The key indicators are prescription growth, repeat prescribing, payer-covered volume, gross-to-net deductions, and the share of prescriptions paid without manufacturer assistance.
Mayne Pharma’s financial disclosures have identified women’s health as a strategic growth area and Nextstellis as a principal branded product. The company’s commercial value depends on whether prescription growth outpaces promotional spending and whether the product gains access on commercial formularies.
Revenue quality matters more than gross prescription count. A prescription supported by a copay program can produce lower net revenue than a commercially reimbursed prescription. The product also faces pressure from online contraceptive platforms and digital-health providers that emphasize low-cost generic alternatives.
Exclusivity transition: 2026 onward
The end of NCE exclusivity increases the probability of ANDA filings. Even if a generic cannot launch immediately because of patents, the threat can affect:
- Payer negotiating leverage.
- Inventory management.
- Prescriber willingness to initiate new patients.
- Valuation of the commercial rights.
- Potential licensing or co-promotion arrangements.
- Manufacturer spending on patent litigation.
A first generic entrant could cause rapid price erosion because drospirenone/ethinyl estradiol products have already established the generic substitution model. The impact on Nextstellis would depend on whether generic applicants can legally market the estetrol/drospirenone combination or must design around particular claims.
Post-generic phase
The product could retain a branded niche if it develops strong patient preference, differentiated tolerability data, or favorable payer positioning. However, oral contraceptive brands generally face substantial volume and price pressure after generic entry.
The highest-value asset before generic launch is the combination of brand growth and remaining patent life. The highest-value asset after generic launch would be clinical differentiation that cannot be replicated through simple substitution.
What revenue exposure does Nextstellis create for Mayne Pharma?
Nextstellis is strategically important because it is a branded growth product rather than a mature generic. Its financial contribution is exposed to five variables:
- Net price after rebates and patient assistance.
- Prescription volume and refill persistence.
- Commercial formulary access.
- Promotional efficiency.
- Timing of generic entry.
Mayne Pharma’s exposure is concentrated in the U.S. because the company holds U.S. commercial rights. Mithra retains broader rights and economic interests outside the United States under regional arrangements. The arrangement creates commercial leverage for Mayne but also limits its control over global commercialization and manufacturing economics.
A key valuation issue is whether the product can reach scale before 2026. If brand adoption remains modest at the start of generic eligibility, the NCE expiry will have limited absolute revenue impact. If Nextstellis reaches meaningful share of new oral contraceptive prescriptions, Paragraph IV litigation and patent settlements become more financially important.
What licensing deals and manufacturers are involved?
Mithra developed estetrol and licensed or partnered regional commercialization rights. Mayne Pharma obtained exclusive U.S. commercialization rights for Nextstellis. The product’s economics therefore involve:
- Mithra’s ownership of core estetrol technology and global intellectual property.
- Mayne Pharma’s U.S. sales and marketing investment.
- Contract manufacturing and supply obligations.
- Potential regional licensees outside the United States.
- Transfer-pricing and supply continuity risks.
Manufacturing protection is relevant because estetrol is a specialized active ingredient and may require controlled synthesis, purification, and quality specifications. Process patents can raise entry costs, but they do not create a complete barrier if a generic manufacturer develops an independent non-infringing process.
What patent litigation and settlement risks affect Nextstellis?
The most important future litigation issue is whether ANDA applicants challenge broad combination patents or rely on formulations that avoid them. Litigation risk will increase as the end of NCE exclusivity approaches.
Possible outcomes include:
| Scenario |
Commercial result |
| No timely ANDA challenge |
Brand retains effective exclusivity until a later patent challenge |
| Paragraph IV filing followed by litigation |
FDA approval may be delayed by the 30-month stay |
| Originator victory |
Generic entry moves to patent expiry or settlement date |
| Generic victory |
Early launch and rapid price pressure |
| Settlement with licensed entry |
Controlled generic launch before the latest patent expiry |
| At-risk launch |
Potential damages and accelerated price erosion |
Settlement terms can be more important than nominal patent expiry. A settlement may allow entry several years before a listed patent expires while giving the brand a predictable period of continued exclusivity.
What generic launch scenarios exist for drospirenone and estetrol?
The main scenarios are:
Delayed entry after patent expiry
This is the most favorable outcome for the originator. Nextstellis retains brand pricing until the strongest surviving patent expires.
Settlement-based entry
A generic launches on a negotiated date, potentially with a limited authorized-generic arrangement or other restrictions. This outcome reduces litigation risk but shortens the brand’s effective exclusivity.
Early entry after patent invalidation
A successful Paragraph IV challenge could produce rapid price and volume erosion. Combination patents would be the central battleground.
Limited-label entry
A generic could initially omit patented indications or uses, although this is less important for a contraceptive product with a relatively focused label.
How does the U.S. market compare with international markets?
The U.S. market has the greatest commercial value because of its size, reimbursement infrastructure, and higher branded pricing. It also has the clearest ANDA and Orange Book framework.
International markets differ in:
- National reimbursement controls.
- Contraceptive procurement systems.
- Reference-pricing rules.
- Patent enforcement standards.
- Regulatory approval timing.
- Brand substitution practices.
Mithra’s international commercialization strategy has depended on regional partners and local approvals. Estetrol’s commercial success outside the United States depends less on premium direct-to-consumer branding and more on government reimbursement, physician adoption, and local pricing.
Key Takeaways
- Drospirenone and estetrol are commercialized in Nextstellis, a branded oral contraceptive approved by the FDA in April 2021.
- Estetrol created five-year NCE exclusivity that runs approximately through April 2026.
- Patent protection may extend into the 2030s, but effective exclusivity depends on surviving composition, formulation, method-of-use, and manufacturing claims.
- The primary competitive threat is generic drospirenone/ethinyl estradiol, which has lower pricing and stronger payer access.
- Nextstellis is exposed to Paragraph IV litigation after the fourth year of NCE exclusivity.
- No biosimilar pathway applies because Nextstellis is a small-molecule drug.
- Mayne Pharma’s financial upside depends on prescription growth, payer coverage, net pricing, and commercial efficiency before generic entry.
- The largest valuation risk is a successful early generic challenge or a settlement that permits entry before the latest patent expiry.
- The patent estate is commercially relevant but must be assessed claim by claim rather than by patent count.
- Long-term brand value depends on measurable clinical differentiation and patient persistence, not only on patent duration.
FAQs
Is drospirenone and estetrol the same as Yaz?
No. Yaz contains drospirenone and ethinyl estradiol. Nextstellis contains drospirenone and estetrol. The progestin is the same, but the estrogen component is different.
Can a generic company copy Nextstellis after April 2026?
Not automatically. The end of NCE exclusivity permits FDA review and potential approval of an ANDA, but listed patents, Paragraph IV litigation, settlements, and court decisions can delay or prevent launch.
Does Nextstellis have biologic or biosimilar competition?
No. Nextstellis is a small-molecule oral tablet. Competitive applications would generally proceed through the ANDA pathway rather than the biosimilar pathway.
Why does estetrol matter commercially?
Estetrol gives Nextstellis a differentiated estrogen component and supports product positioning around selective estrogen activity. Whether that translates into durable revenue depends on clinical evidence, payer coverage, and patient demand.
What would most reduce Nextstellis valuation?
The largest risks are weak prescription growth, poor commercial formulary access, high promotional costs, a successful Paragraph IV challenge, or a settlement that allows generic entry earlier than expected.
References
- U.S. Food and Drug Administration. (2021). FDA approves new oral contraceptive, Nextstellis.
- U.S. Food and Drug Administration. (2021). Nextstellis prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Mayne Pharma Group Limited. (2021). Annual report 2021.
- Mayne Pharma Group Limited. (2022). Annual report 2022.
- Mayne Pharma Group Limited. (2023). Annual report 2023.
- Mithra Pharmaceuticals SA. (2021). Estetrol and Nextstellis commercialization disclosures.
- U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent application information for estetrol-containing pharmaceutical compositions.
